Second-line chemo for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people whose esophageal cancer didn't respond to or couldn't tolerate the first treatment. The goal is to see if this second-line therapy can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that cannot be removed by surgery.
- Your first cancer treatment stopped working or caused too many side effects.
- You have at least one tumor that can be measured on a scan.
- You are generally well enough to be up and about (able to do light activity) and your vital organs are working well (liver, kidneys, blood counts).
- You have not had irinotecan or liposomal irinotecan before as part of your first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies giving combined chemotherapy and radiation to treat esophageal cancer that has returned after earlier surgery and/or prior treatments. It may help control the cancer in the area where it comes back, especially when the surgical margins were not fully clear or the cancer is outside the original radiation field.
This trial tests adding liposomal irinotecan to standard chemotherapy and radiation for locally advanced esophageal squamous cell cancer. The goal is to see if this combination works better than current treatments.
This trial tests a new combination of two drugs—simmitinib (a targeted therapy) and irinotecan (a chemotherapy)—for people with advanced esophageal cancer that has stopped responding to one prior treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.